P18 Adjusted Comparison of Teclistamab Versus Real-World Physician’s Choice (RWPC) of Therapy in Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
Year: 2023
Type: conference-abstract
Source: Value in Health
Authors: M.V. Mateos, A. Chari, S.Z. Usmani, H. Goldschmidt, K. Weisel, K. Qi, A. Londhe, S. Nair, X. Lin, L. Pei, E. Ammann, K. Chastain, T. Parekh, A. Marshall, M. Slavcev, P. Moreau
Institutions: Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cáncer, Centro de Investigación Biomédica en Red de Cáncer, Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, Heidelberg University, University Hospital Heidelberg, University Medical Center Hamburg-Eppendorf, Janssen (Belgium), Janssen Research & Development (United States), Nantes Université
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4390126993